Maplight Therapeutics (NASDAQ:MPLT) Trading Up 10.5% – What’s Next?

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) traded up 10.5% on Monday . The stock traded as high as $20.11 and last traded at $19.92. 90,209 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 167,899 shares. The stock had previously closed at $18.02.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on MPLT shares. Leerink Partners began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective on the stock. Jefferies Financial Group began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $28.00 price target for the company. Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target on the stock. Finally, Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $31.00.

Maplight Therapeutics Stock Performance

The business’s 50 day simple moving average is $16.75.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.